Skip to main content

and
  1. Article

    Open Access

    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

    Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann in Leukemia (2024)

  2. No Access

    Article

    Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

    Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could im...

    Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil in Leukemia (2023)

  3. No Access

    Article

    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

    In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation che...

    Peter Paschka, Richard F Schlenk, Daniela Weber, Axel Benner, Lars Bullinger in Leukemia (2018)